



Food and Drug Administration  
CBER/OCBQ/DBSQC

**From:** Hsiaoling Wang, Ph.D. LACBRP, DBSQC

Alfred Del Grosso, Ph.D. LACBRP, DBSQC

**Subject:** Testing Memo for (b) (4) of Immune Globulin  
Subcutaneous (Human), 20% Solution, STN: 125596/0, from Baxalta

**Through:** Lokesh Bhattacharyya, Ph.D. Lab Chief LACBRP, DBSQC

William McCormick, Ph.D. Director DBSQC

### Summary

Three lots of Immune Globulin Subcutaneous (Human), 20% Solution drug product (DP) were tested for (b) (4) by (b) (4) following the manufacturer's SOP. DBSQC results are in compliance with the DP specifications for lot release as proposed by Baxalta, which include that IgG (b) (4)

### Method

(b) (4)

### Results

(b) (4)

1 page has been determined to be not releasable: (b)(4)